Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NP-101 in High-Risk COVID-19 Patients
NCT05785390Phase 2Terminated
- Sponsor
- Novatek Pharmaceuticals
- Start
- Feb 2023
- Primary completion
- May 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of NP-101 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Novatek Pharmaceuticals. Primary endpoints: Maximum Tolerated Daily Dose at 14 days, Safety and Tolerability of NP-101 vs Placebo at Day 45 and 1 more. Started Feb 2023; status: terminated.
02
Drugs
NP-101
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05785390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05785390.